Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Avadel Pharmaceuticals Plc (AVDL)

Avadel Pharmaceuticals Plc (AVDL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 260,278
  • Shares Outstanding, K 37,450
  • Annual Sales, $ 103,270 K
  • Annual Income, $ -95,300 K
  • 60-Month Beta 1.82
  • Price/Sales 3.85
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.46
  • Growth Rate Est. (year over year) +217,273.91%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.32 +13.06%
on 01/27/20
8.40 -15.00%
on 01/22/20
-0.49 (-6.42%)
since 01/17/20
3-Month
4.98 +43.31%
on 11/20/19
8.49 -15.90%
on 01/17/20
+2.33 (+48.44%)
since 11/19/19
52-Week
1.03 +593.20%
on 04/29/19
8.49 -15.90%
on 01/17/20
+4.95 (+226.03%)
since 02/19/19

Most Recent Stories

More News
Jazz (JAZZ) Submits NDA for Xyrem Follow-On Candidate JZP-258 (Revised)

Jazz (JAZZ) files regulatory application seeking approval for JZP-258, a low sodium formulation of Xyrem, in the United States.

NVS : 97.22 (+0.02%)
AVDL : 7.14 (+2.73%)
JAZZ : 137.62 (+0.58%)
TEVA : 13.45 (+9.17%)
Jazz (JAZZ) Submits NDA for Xyrem Follow-On Candidate JZP-258

Jazz (JAZZ) files regulatory application seeking approval for JZP-258, a low sodium formulation of Xyrem, in the United States.

NVS : 97.22 (+0.02%)
AVDL : 7.14 (+2.73%)
JAZZ : 137.62 (+0.58%)
TEVA : 13.45 (+9.17%)
Jazz's (JAZZ) New Sleep Drug Sunosi Gets Approval in Europe

Jazz (JAZZ) receives approval for Sunosi as a treatment for excessive daytime sleepiness in narcolepsy or obstructive sleep apnea patients in Europe.

NVS : 97.22 (+0.02%)
AVDL : 7.14 (+2.73%)
JAZZ : 137.62 (+0.58%)
TEVA : 13.45 (+9.17%)
LongueVue Capital Adds Experienced Healthcare Operating Partners to Support New & Existing Investments

LongueVue Capital Partners ("LVC"), a partnership-driven, operator-centric private equity firm based in New Orleans with approximately $500 million of assets under management, announced today that Geoff...

AVDL : 7.14 (+2.73%)
BDX : 256.07 (+0.03%)
Avadel (AVDL) Is Up 21.13% in One Week: What You Should Know

Does Avadel (AVDL) have what it takes to be a top stock pick for momentum investors? Let's find out.

AVDL : 7.14 (+2.73%)
5 Top-Ranked ADRs That More Than Doubled the S&P 500 in 2019

Though international markets trailed the U.S. market in 2019, there are hidden gems that crushed the S&P 500 this year on stock-specific strength.

VIPS : 13.67 (-2.77%)
EFA : 68.99 (+0.33%)
VGK : 58.59 (+0.65%)
AIA : 66.17 (+0.78%)
EEM : 44.23 (+0.73%)
AVDL : 7.14 (+2.73%)
SBGL : 13.25 (+10.23%)
EDU : 141.76 (+2.01%)
RCEL : 11.04 (+1.94%)
FLN : 22.52 (+1.01%)
Avadel (AVDL) is a Great Momentum Stock: Should You Buy?

Does Avadel (AVDL) have what it takes to be a top stock pick for momentum investors? Let's find out.

AVDL : 7.14 (+2.73%)
Avadel Pharmaceuticals Completes Enrollment in the REST-ON Phase 3 Pivotal Trial of FT218 for Excessive Daytime Sleepiness and Cataplexy in Patients with Narcolepsy

- - -

AVDL : 7.14 (+2.73%)
Avadel Pharmaceuticals Receives U.S. FDA Approval for Nouress(TM) (AV001), a Cysteine Hydrochloride Injection for Treating Neonate Patients Requiring Total Parental Nutrition (TPN)

Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating narcolepsy, announced today that the U.S. Food...

AVDL : 7.14 (+2.73%)
Avadel Pharmaceuticals Appoints Dr. Mark McCamish to its Board of Directors

Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating narcolepsy, announced today the appointment...

FTSV : 47.55 (+4.16%)
AVDL : 7.14 (+2.73%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade AVDL with:

Business Summary

Avadel Pharmaceuticals plc is a specialty pharmaceutical company. Its product pipeline consists of hospital and paediatrics. Hospital segment provides Bloxiverz(R), Vazculep(R) and Akovaz(TM). Paediatrics segment provides Karbinal (TM) ER, AcipHex(R) Sprinkle and Flexichamber(TM). The company operates...

See More

Key Turning Points

2nd Resistance Point 7.35
1st Resistance Point 7.25
Last Price 7.14
1st Support Level 6.97
2nd Support Level 6.79

See More

52-Week High 8.49
Last Price 7.14
Fibonacci 61.8% 5.64
Fibonacci 50% 4.76
Fibonacci 38.2% 3.88
52-Week Low 1.03

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar